These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7585861)

  • 1. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 2. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
    Ginsberg HN
    Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering drugs: focus on HMG-CoA reductase inhibitors. Introduction.
    Thompson GR
    Atherosclerosis; 1991 Dec; 91 Suppl():S1-2. PubMed ID: 1789811
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering therapy for the primary prevention of coronary heart disease.
    Gotto AM
    J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and coronary heart disease.
    Fey R; Pearson N
    Lancet; 1996 May; 347(9012):1389-90. PubMed ID: 8637349
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
    Shviro I; Leitersdorf E
    Cardiology; 1996; 87(6):469-75. PubMed ID: 8904672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the problem of under-treatment.
    McCabe C
    Am J Cardiovasc Drugs; 2003; 3(3):179-91. PubMed ID: 14727930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.